Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation.
about
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsHIV-1 Vif, APOBEC, and intrinsic immunityCyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCFcyclin F E3 Ligase MachineryRegulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaquesVif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.MDM2 is a novel E3 ligase for HIV-1 Vif.Advances in the structural understanding of Vif proteinsInteractions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif.Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3GTumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis.CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.Mutational analysis of HIV-2 Vpx shows that proline residue 109 in the poly-proline motif regulates degradation of SAMHD1.Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.HIV-1 Vif: a guardian of the virus that opens up a new era in the research field of restriction factorsPolyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif.A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis".Expression studies of the core+1 protein of the hepatitis C virus 1a in mammalian cells. The influence of the core protein and proteasomes on the intracellular levels of core+1.Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection.Role of poly-proline motif in HIV-2 Vpx expression.Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination.Introduction of H2C2-type zinc-binding residues into HIV-2 Vpr increases its expression level.
P2860
Q24619114-39674043-81B6-4194-BF6B-9E350F8E7EA9Q24647833-38ABDB50-1718-4291-A3BC-AFCCA71E3653Q33567848-EAE67DF5-6DCA-4166-826A-DB5D1C1C3E58Q33908716-7FC82A79-05B2-4E05-B126-121FDC46CF4FQ34166447-CC8F001D-71D3-4C90-905E-003D44A0CB9CQ34179686-7F1173D1-3775-48FF-A637-C87843B0DA36Q35024235-8CD28213-D458-4B78-AD74-C6D64C653963Q35046349-CDA0F22D-EF56-4949-8C4C-1F87051D64B9Q35947645-5B5B786A-144E-475A-A563-D8A289175B31Q36249419-7D8607E6-487A-49F3-B7A7-3C3D89EE8011Q37069041-9E4BEE83-AE60-49BB-B97F-AA8843C1F5C3Q37108363-6AE5EF9B-BAA7-4187-B382-ACA6F6D9B4B6Q37153444-7CCB9797-57F1-4429-8BE2-F555C93DE046Q37204580-A6E6B787-A778-4607-951B-0D081C14E792Q37504507-5199FDFE-7129-44C1-A922-70110AC122D7Q37605560-9F36B884-CDCE-4644-92C1-B2DFC8B80F26Q37714020-E2920C05-301C-418C-8E8F-DCB775D01F04Q38739726-C9CB1864-14D0-4CDE-8CED-173258BD1A75Q38879647-79D4CCD0-21B1-40B0-A901-D0F5D0053697Q39200129-588EFFE5-2EFD-4ACE-80CF-AE0D06B25524Q39463408-6DB2E60A-2679-4454-B293-140EACC4ECC5Q39741166-E25E6DFD-949E-403D-BE01-38404DA00F5EQ40075991-444ADBC1-33B7-45A1-9FD1-0674AFFF250FQ40103032-1B7112FE-B191-47B7-BF38-92B4D2E7C2C8Q40634933-F309031F-51F8-438A-A6D0-3094C9FE058CQ41837180-4844C680-4B7C-4542-AC01-F8CA27E9C3B1Q42712951-DCA5C249-0453-42DD-85AE-351D78BF223DQ46954025-C1E47D90-7EDA-4167-9C6D-0812A6948FAAQ47555671-E8F135DD-D8E8-47F7-8EDB-B7E847F68494
P2860
Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Expression of HIV-1 accessory ...... mal by proteasome degradation.
@en
type
label
Expression of HIV-1 accessory ...... mal by proteasome degradation.
@en
prefLabel
Expression of HIV-1 accessory ...... mal by proteasome degradation.
@en
P2093
P1476
Expression of HIV-1 accessory ...... mal by proteasome degradation.
@en
P2093
Akiko Sakurai
Akiko Yoshida
Akio Adachi
Keiji Tanaka
Klaus Strebel
Mikako Fujita
Tomoki Chiba
P304
P356
10.1016/J.MICINF.2004.04.011
P577
2004-07-01T00:00:00Z